{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:42:14Z","timestamp":1792435334700,"version":"4.5.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite the high incidence of COVID-19 worldwide, clinical experience with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) in inborn errors of immunity remains limited. Recent studies have shown that patients with defects in type 1 interferon (IFN)-related pathways or those with autoantibodies against type 1 IFNs develop severe COVID-19. We reported the clinical course of 22 patients with CTLA-4 insufficiency and COVID-19 and retrospectively examined autoantibodies against type 1 IFNs at baseline. Data were obtained from the patient interviews and chart reviews. Screening for anti-IFN autoantibodies was performed using a multiplex particle-based assay. Student t test, Mann Whitney, analysis of variance, or \u03c72 tests were used where appropriate. Twenty-two patients aged from 8\u00a0months to 54 years, with genetically confirmed CLTA-4 insufficiency, developed COVID-19 from 2020 to 2022. The most common symptoms were fever, cough, and nasal congestion, and the median duration of illness was 7.5\u00a0days. Twenty patients (91%) developed mild COVID-19 and were treated as outpatients. Two patients were hospitalized because of COVID-19 pneumonia but did not require mechanical ventilation. Ten (45%) patients were vaccinated at the time of their first COVID-19 infection. Eleven patients received outpatient treatment with monoclonal antibodies against the SARS-CoV-2 spike protein. During the study period, 17 patients were vaccinated against SARS-CoV-2, with no severe vaccine-related adverse effects. Although median anti-S titers following vaccination or infection were lower in patients receiving immunoglobulin replacement therapy (IGRT) (349 IU\/dL) than in those not receiving IGRT (2594 IU\/dL; P\u00a0= .15); 3 of 9 patients on IGRT developed titers &amp;gt;2000 IU\/dL. All patients tested negative for autoantibodies against IFN-\u03b1, IFN-\u03b2, and IFN-\u03c9 at baseline. Most patients with CTLA-4 insufficiency and COVID-19 had nonsevere disease, lacked autoantibodies against type 1 IFNs, and tolerated messenger RNA vaccines with few adverse effects. Whether our findings can be extrapolated to patients receiving CTLA-4-targeting checkpoint inhibitors requires further studies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010105","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T19:04:42Z","timestamp":1688583882000},"page":"5743-5751","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Management and outcome of COVID-19 in CTLA-4 insufficiency"],"prefix":"10.1182","volume":"7","author":[{"given":"Sebastian","family":"Ochoa","sequence":"first","affiliation":[{"name":"1Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2234-2813","authenticated-orcid":false,"given":"Michael S.","family":"Abers","sequence":"additional","affiliation":[{"name":"1Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey B.","family":"Rosen","sequence":"additional","affiliation":[{"name":"1Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rump","sequence":"additional","affiliation":[{"name":"1Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5814-2795","authenticated-orcid":false,"given":"Katherine","family":"Howe","sequence":"additional","affiliation":[{"name":"1Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay A.","family":"Lieberman","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, The University of Tennessee Health Science Center, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7586-4722","authenticated-orcid":false,"given":"Benjamin L.","family":"Wright","sequence":"additional","affiliation":[{"name":"3Division of Allergy, Asthma and Clinical Immunology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, AZ"},{"name":"4Section of Allergy and Immunology, Division of Pulmonology, Phoenix Children\u2019s Hospital, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Suez","sequence":"additional","affiliation":[{"name":"5Allergy, Asthma & Immunology Clinic, PA, Irving, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0385-033X","authenticated-orcid":false,"given":"M\u00e1t\u00e9","family":"Krausz","sequence":"additional","affiliation":[{"name":"6Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6897-6806","authenticated-orcid":false,"given":"Bodo","family":"Grimbacher","sequence":"additional","affiliation":[{"name":"6Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail S.","family":"Lionakis","sequence":"additional","affiliation":[{"name":"1Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulbu","family":"Uzel","sequence":"additional","affiliation":[{"name":"1Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"2","key":"2023101012505920000_bib1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: an international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6515","key":"2023101012505920000_bib2","doi-asserted-by":"crossref","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"issue":"6515","key":"2023101012505920000_bib3","doi-asserted-by":"crossref","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"7","key":"2023101012505920000_bib4","doi-asserted-by":"crossref","first-page":"e20210554","DOI":"10.1084\/jem.20210554","article-title":"Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1","volume":"218","author":"Bastard","year":"2021","journal-title":"J\u00a0Exp Med"},{"issue":"6204","key":"2023101012505920000_bib5","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"issue":"12","key":"2023101012505920000_bib6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"issue":"6","key":"2023101012505920000_bib7","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"2023101012505920000_bib8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"issue":"5899","key":"2023101012505920000_bib9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"2023101012505920000_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clim.2018.06.010","article-title":"CTLA-4 regulates human Natural Killer cell effector functions","volume":"194","author":"Lougaris","year":"2018","journal-title":"Clin Immunol"},{"issue":"1","key":"2023101012505920000_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imr.12721","article-title":"What did we learn from CTLA-4 insufficiency on the human immune system?","volume":"287","author":"Mitsuiki","year":"2019","journal-title":"Immunol Rev"},{"key":"2023101012505920000_bib12","unstructured":"National Institutes of Health\n          . Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2021. Accessed 6 May 2022. https:\/\/www.covid19treatmentguidelines.nih.gov\/."},{"issue":"8","key":"2023101012505920000_bib13","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1002\/cpz1.511","article-title":"Detection of neutralizing anti-type 1 interferon autoantibodies","volume":"2","author":"Shaw","year":"2022","journal-title":"Curr Protoc"},{"issue":"19","key":"2023101012505920000_bib14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19--final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023101012505920000_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2023101012505920000_bib16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"2023101012505920000_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"2023101012505920000_bib18","doi-asserted-by":"crossref","first-page":"720205","DOI":"10.3389\/fimmu.2021.720205","article-title":"SARS-CoV-2 spike protein-directed monoclonal antibodies may ameliorate COVID-19 complications in APECED patients","volume":"12","author":"Ferre","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"2023101012505920000_bib19","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5743\/2083711\/blooda_adv-2023-010105-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/19\/5743\/2083711\/blooda_adv-2023-010105-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T12:51:22Z","timestamp":1696942282000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/19\/5743\/496748\/Management-and-outcome-of-COVID-19-in-CTLA-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":19,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,10,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010105","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}